Abstract:Abstract Background PFKP (phosphofructokinase, platelet), a rate-limiting enzyme of glycolysis, plays a decisive role in various human physio pathological processes. Multiple function of PFKP in different cancer types was reported, including lung cancer, breast cancer et al. However, systematic pan-cancer analysis of PFKP has not been performed now, which could reflect its clinically value about diagnosis, prognosis, drug sensitivity, and immunological correlation. Methods Systematic bioinformation analysis of PFKP was performed based on several public datasets including TCGA (The Cancer Genome Atlas), CCLE (Cancer Cell Line Encyclopedia), GTEx (Genotype-Tissue Expression Project), and HPA (Human Protein Atlas). Prospective carcinogenesis of PFKP in pan-cancer was estimated by expression analysis, effect on patients’ prognosis, diagnosis significant evaluation, and immunity regulation estimation. Then, pan-cancer function enrichment of PFKP was also accessed through its effect on signaling score and gene expression profile. Finally, upstream expressing regulation of PFKP was explored by promoter DNA methylation and transcription factors (TFs) prediction. Results Our analysis revealed that highly expression of PFKP was found in most cancer types. Meanwhile, high level of PFKP displayed a significant correlation with poor prognosis of patients across pan-cancer. And a fine diagnosis value of PFKP was summarized, especially in its positive correlation with PD-L1 (programmed cell death-Ligand 1). Then, we also found an obvious immunity regulating effect of PFKP in most cancer types. PFKP also had a remarkably negative correlation with several cancer drugs. Finally, ectopic expression of PFKP may depend on DNA methylation and several predicated transcription factors, including KLF (KLF transcription factor) and Sp (Sp transcription factor) family. Conclusion This pan-cancer analysis revealed that high expression level of PFKP might be a fine biomarker and predictor in most cancer types. Meanwhile, performance of PFKP across pan-cancer also implied its meaningful role in cancer immunity regulation even in immunotherapy and drug resistance. All in all, PFKP might be explored as an aux monitor for pan-cancer early prognosis and diagnosis.

Differential Phosphofructokinase-1 Isoenzyme Patterns Associated with Glycolytic Efficiency in Human Breast Cancer and Paracancer Tissues.

Phosphofructokinase 1 Glycosylation Regulates Cell Growth and Metabolism

Expression of Phosphofructokinase-1 and Glycolytic Level in Human Breast Cancer and Paracancer Tissues

Phosphofructokinase-1 in Cancer: A Promising Target for Diagnosis and Therapy

6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 and 4: A pair of valves for fine-tuning of glucose metabolism in human cancer

High Expression of Metabolic Enzyme PFKFB4 is Associated with Poor Prognosis of Operable Breast Cancer.

Phosphofructokinase Platelet Overexpression Accelerated Colorectal Cancer Cell Growth and Motility

Glycolysis rate-limiting enzyme PFKP: A pan-cancer predictor for prognostic significant, immunological correlation, and drug sensitivity prediction

Platelet isoform of phosphofructokinase promotes aerobic glycolysis and the progression of non‐small cell lung cancer

Role of PFKFB3 and PFKFB4 in Cancer: Genetic Basis, Impact on Disease Development/Progression, and Potential as Therapeutic Targets

Glycolytic reprogramming in cancer cells: PKM2 dimer predominance induced by pulsatile PFK-1 activity

PFKP is a prospective prognostic, diagnostic, immunological and drug sensitivity predictor across pan-cancer

Cancer-associated somatic mutations in human phosphofructokinase-1 reveal a critical electrostatic interaction for allosteric regulation of enzyme activity

A comprehensive prognostic and immunological implications of PFKP in pan-cancer

Figure S5 from P38γ MAPK is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis

PFKP is Transcriptionally Repressed by BRCA1/ZBRK1 and Predicts Prognosis in Breast Cancer.

Dysregulation of phosphoenolpyruvate carboxykinase in cancers: A comprehensive analysis

Expression of Phosphoglycerate Mutase 1 and Its Significance in Breast Carcinoma and Corresponding Normal Tissues

Expression of 6-phosphofructokinase-2 in colorectal cancer and its clinical significance

Fructose 2,6-Bisphosphate in Cancer Cell Metabolism

HRD1 Elicitation of An Anti-Warburg Effect by Targeting PFKP to Inhibit Breast Cancer Growth and Progression